By learning about the implications of all transplant-related medications and treatments before undergoing a transplant, men with cystic fibrosis can avoid some of the harmful reproductive side effects and improve their ability to have biological children post-transplant.
Site Search
Positive results from a study of ivacaftor (Kalydeco®) in children ages 1 to 2 were announced today.
Sex and relationships are essential parts of life. For some people with CF, making the distinction between sexuality and intimacy can be an important step in navigating the ups and downs of having a chronic illness.
For some people with CF, having sex can come with physical discomfort, aggravations and pain. Fortunately, some practical tips and advice can help both men and women with CF fully enjoy their sex lives.
Two Phase 3 clinical trials of tezacaftor (VX-661) in combination with ivacaftor (Kalydeco®) showed positive results, Vertex Pharmaceuticals announced today.
Assisted reproductive technology (ART) is often a popular family building option among people with cystic fibrosis. Learn more about common ART techniques to find the right family building method for you.
By learning more about the pros and cons of adoption for a person with cystic fibrosis, you can ultimately decide if it is the right family building option for you.
More women with cystic fibrosis are reaching reproductive age, becoming pregnant, and delivering babies. Nutrition before and during pregnancy is essential for all women.
Today, Vertex Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration has accepted its application to expand Trikafta® (elexacaftor/tezacaftor/ivacaftor) to include children ages 6-11 years old with cystic fibrosis who have at least one F508del or a mutation in the CFTR gene that is responsive based on in vitro data. The FDA has granted priority review of the application and has indicated that it will make a decision by June 8, 2021.